BofA/Merrill Lynch Downgrades Mednax (MD) to Underperform
Tweet
Share
E-mail
Get Alerts MD Hot Sheet
Price: $26.56 --0%
Rating Summary:
6 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 10
Rating Summary:
6 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 10
Join SI Premium – FREE
BofA/Merrill Lynch analyst Kevin Fischbeck downgraded Mednax (NYSE: MD) from Neutral to Underperform.
For an analyst ratings summary and ratings history on Mednax click here. For more ratings news on Mednax click here.
Shares of Mednax closed at $21.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Pediatrix Medical Group (MD) to Hold
- Lyntris said to price IPO in lower half of range
- BofA Adjusts US 1 List
Create E-mail Alert Related Categories
DowngradesRelated Entities
BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
